We are live on ! Find out more
MIRM icon

Mirum Pharmaceuticals

272 hedge funds and large institutions have $4.2B invested in Mirum Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 74 funds opening new positions, 91 increasing their positions, 77 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

429% more first-time investments, than exits

New positions opened: 74 | Existing positions closed: 14

49% more capital invested

Capital invested by funds: $2.82B → $4.2B (+$1.38B)

27% more funds holding

Funds holding: 214272 (+58)

18% more repeat investments, than reductions

Existing positions increased: 91 | Existing positions reduced: 77

11% more funds holding in top 10

Funds holding in top 10: 910 (+1)

2.32% more ownership

Funds ownership: 111.83%114.15% (+2.3%)

8% less call options, than puts

Call options by funds: $7.16M | Put options by funds: $7.75M

Holders
272
Holders Change
+58
Holders Change %
+27.1%
% of All Funds
3.57%
Holding in Top 10
10
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+11.11%
% of All Funds
0.13%
New
74
Increased
91
Reduced
77
Closed
14
Calls
$7.16M
Puts
$7.75M
Net Calls
-$587K
Net Calls Change
+$2.92M
Name Holding Trade Value Shares
Change
Change in
Stake
FTM
26
First Turn Management
California
$41.8M +$2.74M +43,029 +8%
WP
27
Woodline Partners
California
$41.6M
Pictet Asset Management
28
Pictet Asset Management
Switzerland
$39.7M -$10.2M -159,879 -23%
Loomis, Sayles & Company
29
Loomis, Sayles & Company
Massachusetts
$39.5M -$885K -13,917 -3%
BCM
30
Boone Capital Management
Georgia
$39.3M -$6.72M -105,716 -16%
Renaissance Technologies
31
Renaissance Technologies
New York
$37.6M +$7.44M +117,100 +30%
Adage Capital Partners
32
Adage Capital Partners
Massachusetts
$36.5M +$16.2M +254,468 +105%
Connor, Clark & Lunn Investment Management (CC&L)
33
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$36.4M +$4.59M +72,232 +17%
Goldman Sachs
34
Goldman Sachs
New York
$33.1M +$3.55M +55,830 +14%
Bank of New York Mellon
35
Bank of New York Mellon
New York
$32.7M -$3.21M -50,534 -10%
CS
36
Candriam SCA
Luxembourg
$29.5M +$1.91M +30,021 +8%
Charles Schwab
37
Charles Schwab
California
$28.9M +$720K +11,329 +3%
Macquarie Group
38
Macquarie Group
Australia
$28.8M -$2.7M -42,505 -10%
Bank of America
39
Bank of America
North Carolina
$28.6M +$76.5K +1,204 +0.3%
Voloridge Investment Management
40
Voloridge Investment Management
Florida
$28.6M +$23.6M +371,999 +2,117%
Northern Trust
41
Northern Trust
Illinois
$28.2M -$1.08M -17,060 -4%
EA
42
Emerald Advisers
Pennsylvania
$27.1M +$4.06M +63,834 +21%
NCGI
43
Next Century Growth Investors
Minnesota
$26.5M +$10.8M +170,609 +90%
Federated Hermes
44
Federated Hermes
Pennsylvania
$25.4M +$141K +2,218 +0.6%
Two Sigma Investments
45
Two Sigma Investments
New York
$25.2M +$10.9M +171,312 +100%
Balyasny Asset Management
46
Balyasny Asset Management
Illinois
$23.3M +$20.2M +317,150 New
William Blair Investment Management
47
William Blair Investment Management
Illinois
$23M +$19.9M +313,259 New
Millennium Management
48
Millennium Management
New York
$22.7M +$1.33M +20,872 +7%
PCM
49
Penn Capital Management
Pennsylvania
$22.6M -$2.18M -34,265 -10%
TCM
50
TimesSquare Capital Management
New York
$22M +$19.1M +300,649 New

MIRM Hedge Fund Activity: Q3 2025 in Review

272 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Mirum Pharmaceuticals (MIRM) for Q3 2025, worth a combined $4.2B — up 49% from $2.82B a quarter earlier.

Buyers outnumbered sellers: 74 funds opened new MIRM positions and 14 closed out — a net gain of 60 holders — while 91 added to existing stakes and 77 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $42.7M. The largest seller was BVF Inc, cutting an estimated $80.5M.

  • 272 institutional investors held Mirum Pharmaceuticals (MIRM) as of Q3 2025, up from 214 in Q2 2025.
  • Funds reported $4.2B of Mirum Pharmaceuticals stock for Q3 2025, up 49% quarter-over-quarter.
  • 74 funds opened new Mirum Pharmaceuticals positions in Q3 2025 and 14 closed out, a net change of +60 holders.
  • The largest Mirum Pharmaceuticals buyer in Q3 2025 was Wellington Management Group, an estimated $42.7M added.
  • The largest Mirum Pharmaceuticals seller in Q3 2025 was BVF Inc, an estimated $80.5M sold.

Based on aggregated 13F filings for Q3 2025.